Detalhe da pesquisa
1.
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.
BJU Int
; 133(3): 297-304, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548533
2.
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Oncologist
; 28(3): e167-e170, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576430
3.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
Oncologist
; 28(9): e748-e755, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36971500
4.
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.
Oncologist
; 28(12): 1079-1084, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432304
5.
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
J Urol
; 209(4): 701-709, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36573926
6.
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study.
Cancer Invest
; 41(1): 70-76, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239609
7.
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
J Genet Couns
; 2023 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37697864
8.
Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
Future Oncol
; 18(1): 21-33, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34766841
9.
Treatment of mature landfill leachate using hybrid processes of hydrogen peroxide and adsorption in an activated carbon fixed bed column.
J Environ Sci Health A Tox Hazard Subst Environ Eng
; 53(3): 238-243, 2018 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29172962
10.
Watershed-Scale Impacts from Surface Water Disposal of Oil and Gas Wastewater in Western Pennsylvania.
Environ Sci Technol
; 51(15): 8851-8860, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28699344
11.
Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
Lancet Oncol
; 22(7): 894-896, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051179
12.
Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
Curr Opin Urol
; 30(5): 740-742, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732626
13.
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
Eur Urol Focus
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580524
14.
The Role of Gut Microbiome in the Pathogenesis and the Treatment of Inflammatory Bowel Diseases.
Cureus
; 16(2): e54569, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38516478
15.
Barriers to Clinical Trial Implementation Among Community Care Centers.
JAMA Netw Open
; 7(4): e248739, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38683608
16.
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Cancer Discov
; : OF1-OF14, 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583184
17.
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol
; 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290965
18.
The Gut Microbiome and Metastatic Renal Cell Carcinoma.
J Clin Med
; 12(4)2023 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36836036
19.
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors.
Clin Genitourin Cancer
; 21(1): 69-75, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36509613
20.
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Front Immunol
; 14: 1274781, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38259453